Founded by a team of researchers from Harvard University, i2O Therapeutics is developing a platform to enable oral delivery of traditionally injectable biological drugs, such as peptides and proteins.

The company’s platform enables drugs that traditionally would not survive the hostile environment of the digestive system to pass through safely by utilizing a unique coating that dissolves in the small intestine, thereby releasing the active drug. i2O’s initial focus is on developing a novel oral formulation for GLP-1 analogs for the treatment of type 2 diabetes.

The technology is based on encapsulating complex drugs with an ionic liquid. The company says that by choosing the right ions it is possible to control the properties, so they can be made more viscous, less viscous, more tissue penetrating, or inert. It has been shown in the lab that a variety of drugs can be delivered, including peptides, small molecules, and antibodies.

As well as diabetes, primary indications are likely to include autoimmune diseases and oncology.

The company’s technology has the potential to enable the oral delivery of high-value drugs in a safer, more effective and patient-friendly way and also by easing the treatment burden for dozens of therapeutics that were previously restricted to intravenous or subcutaneous delivery.

The company has raised funding from Colorcon Ventures, the corporate venture fund of Colorcon Inc, as well as Sanofi Ventures and JDRF T1D Fund.

Subscribe for alerts on new companies featured on Startups.Bio

• Archon BiosciencesNovember 20, 2024
  Archon Biosciences is a biotech company pioneering computationally designed ‘Antibody Cages’ to… Read more: Archon Biosciences
• Cytospire TherapeuticsNovember 13, 2024
  Founded in 2023, Cytospire Therapeutics is developing a portfolio of next-generation immune… Read more: Cytospire Therapeutics
• This Week in Biotech Venture CapitalNovember 4, 2024
  The biotech sector continues to see a strong flow of new venture… Read more: This Week in Biotech Venture Capital
• THRONCATOctober 30, 2024
  THRONCAT is a new startup that aims to transform the field of… Read more: THRONCAT
• Roundup of recent venture funding roundsOctober 21, 2024
  The biotechnology sector is advancing rapidly, fueled by significant venture capital investments… Read more: Roundup of recent venture funding rounds
• Analona TherapeuticsOctober 21, 2024
  Founded in 2024, Analona Therapeutics is a biotech company located in Denmark… Read more: Analona Therapeutics